Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Durham, North Carolina 27710


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed primary malignant glioblastoma multiforme.


Study summary:

OBJECTIVES: - Determine the antitumor activity of temozolomide in adults with newly diagnosed glioblastoma multiforme. - Define the relationship between tumor O6-alkylguanine-DNA alkyltransferase activity and tumor response in these patients. - Define the relationship between tumor DNA mismatch repair activity and tumor response to temozolomide. OUTLINE: Patients receive temozolomide orally once daily on days 1-5. Treatment courses are repeated every 28 days. In the absence of disease progression and toxicity, patients receive up to 4 courses of treatment prior to radiation therapy. After radiation therapy, patients demonstrating partial or complete response may receive an additional 12 courses of treatment. Patients are followed every 8-12 weeks for 2 years. PROJECTED ACCRUAL: This study will accrue 50 patients.


Criteria:

DISEASE CHARACTERISTICS: - Histologically proven, newly diagnosed, supratentorial malignant glioblastoma multiforme not requiring immediate radiation therapy - At least 1 bidimensionally measurable lesion PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 70-100% Life expectancy: - Greater than 12 weeks Hematopoietic: - Absolute neutrophil count at least 1500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGOT and SGPT less than 2.5 times ULN - Alkaline phosphatase less than 2 times ULN Renal: - BUN less than 1.5 times ULN - Creatinine less than 1.5 times ULN Other: - Must be neurologically stable - No systemic disease - No acute infection requiring intravenous antibiotics - No frequent vomiting - No other medical condition that would interfere with oral medication intake such as partial bowel obstruction - No prior or concurrent malignancies except: - Surgically cured carcinoma in situ of the cervix - Basal or squamous cell carcinoma of the skin - HIV negative - No AIDS-related illness - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior biologic therapy - No concurrent biologic therapy (growth factors or erythropoietin) Chemotherapy: - No prior chemotherapy - No other concurrent chemotherapy Endocrine therapy: - Concurrent steroid allowed (must be on stable dose for at least 1 week prior to study) Radiotherapy: - No prior radiation therapy - No prior interstitial brachytherapy - No prior radiosurgery to the brain - Not requiring immediate radiation therapy - No concurrent radiotherapy Surgery: - Recovered from any effects of prior surgery - At least 2 weeks since prior surgical resection Other: - No other concurrent investigational drugs


Study is Available At:


Original ID:

1171


NCT ID:

NCT00003464


Secondary ID:

DUMC-1171-01-6R4


Study Acronym:


Brief Title:

Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme


Official Title:

Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal


Overall Status:

Completed


Study Phase:

Phase 2


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Duke University


Oversight Authority:

United States: Federal Government


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Primary Purpose: Treatment


Number of Arms:

0


Number of Groups:

0


Total Enrollment:

50


Enrollment Type:

Anticipated


Overall Contact Information

Official Name:Henry S. Friedman, MD
Study Chair
Duke University

Study Dates

Start Date:September 1997
Completion Date:August 2003
Completion Type:Actual
Verification Date:October 2009
Last Changed Date:June 19, 2013
First Received Date:November 1, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:temozolomide
Intervention Type:Radiation
Name:radiation therapy

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Duke University
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.